New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
Abraxis BioScience (ABII)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
ABII
»
Topics
»
FORM 10-K/A
This excerpt taken from the
ABII 10-K
filed Apr 30, 2009.
FORM 10-K/A
STYLE="margin-top:12px;margin-bottom:0px">
(Mark One)
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
STYLE="margin-top:12px;margin-bottom:0px; margin-left:5%">
For the fiscal year ended December 31, 2008
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
STYLE="margin-top:12px;margin-bottom:0px; margin-left:5%">
For the transition period from
to
"FORM 10-K/A" elsewhere:
Genzyme (GENZ)
Accentia Biopharmaceuticals (ABPI)
Adherex Technologies (ADH)
Advanced Life Sciences Holdings (ADLS)
Anesiva (ANSV)
Artes Medical (ARTE)
Celldex Therapeutics, Inc. (AVAN)
Avigen (AVGN)
Advancis Pharmaceutical (AVNC)
Avalon Pharmaceuticals (AVRX)
BioSphere Medical (BSMD)
Cell Genesys (CEGE)
CollaGenex Pharmaceuticals (CGPI)
Caraco Pharmaceutical Laboratories (CPD)
CuraGen (CRGN)
Zalicus Inc. (CRXX)
Cypress Bioscience (CYPB)
Digital Angel (DOC)
Datascope (DSCP)
Diversa (DVSA)
Ev3 (EVVV)
PC GROUP, INC. (GAIT)
HLTH (HLTH)
Fibrocell Science, Inc. (ILE)
Lipid Sciences (LIPD)
GALECTIN THERAPEUTICS INC (PRW)
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour